The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

The degree of tumor load reduction after therapy, which is determined by the degrees of
cytoreduction and cytogenetic response, is an important prognostic factor for patients with …

The principle aim of residual disease analysis in patients with chronic myeloid leukaemia
(CML) is to gauge patient response to treatment and, in patients after allogeneic BMT, to …

Recent progress in the development of diagnostic techniques has greatly facilitated the
monitoring of minimal residual disease (MRD) in patients with hematologic neoplasia. The …

We used a recently developed system for real‐time quantitative polymerase chain reaction
(PCR) to determine residual disease in patients with chronic myeloid leukaemia. The …

Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL
fusion transcripts in CML but they are hardly reproducible. In this work, we have developed …

Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches
and clinical aspects. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

We have developed a rapid real‐time quantitative PCR method for measuring BCR‐ABL
mRNA levels in peripheral blood in chronic myeloid leukaemia (CML). The technique was …

BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

For patients with chronic myeloid leukaemia, methods for monitoring response to treatment
have changed considerably in recent years. In the 1980s, the principal approach was …